comparemela.com

Latest Breaking News On - Evaluate psilocybin experiential training - Page 1 : comparemela.com

Numinus Wellness Inc receives clinical trial application approval from Health Canada for experiential psychedelic-assisted therapy training using Psilocybe cubensis tea

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) announced that it has received approval from Health Canada for its experiential training study that will test.

British columbiaPayton nyquvestPaul thielkingNuminus bioscience enfiniteaNuminus wellness incPractitioner training programHealth canadaAccess programNuminus wellnessSingle arm studyEvaluate psilocybin experiential trainingHealthy volunteersExpand knowledgeTherapists planningConduct psilocybin assisted therapyNuminus bioscience

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and.

British columbiaPayton nyquvestPaul thielkingNuminus bioscience enfiniteaNuminus wellness incNuminu practitioner training programHealth canadaAccess programNuminus biosciencePsilocybin teaChief science officerSingle arm studyEvaluate psilocybin experiential trainingHealthy volunteersExpand knowledgeTherapists planning

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and.

British columbiaNuminus bioscienceSharan sidhuPaul thielkingNuminus bioscience enfiniteaScientific researchNuminus wellness incInnovation laboratory operationsCanada special access programmeHealth canadaPsilocybin teaNuminus wellnessPsilocybin assisted therapyChief science officerSingle arm studyEvaluate psilocybin experiential training

vimarsana © 2020. All Rights Reserved.